Virginia Commonwealth University

VCU Scholars Compass
Internal Medicine Publications

Dept. of Internal Medicine

2006

Systemic inflammatory response syndrome in adult
patients with nosocomial bloodstream infections
due to enterococci
Katharine Bar
Virginia Commonwealth University, katharinebar@gmail.com

Hilmar Wisplinghoff
University of Cologne

Richard P. Wenzel
Virginia Commonwealth University, rwenzel@mail2.vcu.edu

Gonzalo M. L. Bearman
Virginia Commonwealth University, gbearman@mcvh-vcu.edu

Michael B. Edmond
Virginia Commonwealth University, medmond@mcvh-vcu.edu

Follow this and additional works at: http://scholarscompass.vcu.edu/intmed_pubs
© 2006 Bar et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.

Downloaded from
http://scholarscompass.vcu.edu/intmed_pubs/15

This Article is brought to you for free and open access by the Dept. of Internal Medicine at VCU Scholars Compass. It has been accepted for inclusion
in Internal Medicine Publications by an authorized administrator of VCU Scholars Compass. For more information, please contact
libcompass@vcu.edu.

BMC Infectious Diseases

BioMed Central

Open Access

Research article

Systemic inflammatory response syndrome in adult patients with
nosocomial bloodstream infections due to enterococci
Katharine Bar1, Hilmar Wisplinghoff2, Richard P Wenzel1,
Gonzalo ML Bearman1 and Michael B Edmond*1
Address: 1Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA, USA and 2Institute for Medical Microbiology,
Immunology and Hygiene, University of Cologne, Cologne, Germany
Email: Katharine Bar - katharinebar@gmail.com; Hilmar Wisplinghoff - hwisplinghoff@hotmail.com; Richard P Wenzel - rwenzel@vcu.edu;
Gonzalo ML Bearman - gbearman@vcu.edu; Michael B Edmond* - medmond@vcu.edu
* Corresponding author

Published: 26 September 2006
BMC Infectious Diseases 2006, 6:145

doi:10.1186/1471-2334-6-145

Received: 31 May 2006
Accepted: 26 September 2006

This article is available from: http://www.biomedcentral.com/1471-2334/6/145
© 2006 Bar et al; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0),
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract
Background: Enterococci are the third leading cause of nosocomial bloodstream infection (BSI).
Vancomycin resistant enterococci are common and provide treatment challenges; however
questions remain about VRE's pathogenicity and its direct clinical impact. This study analyzed the
inflammatory response of Enterococcal BSI, contrasting infections from vancomycin-resistant and
vancomycin-susceptible isolates.
Methods: We performed a historical cohort study on 50 adults with enterococcal BSI to evaluate
the associated systemic inflammatory response syndrome (SIRS) and mortality. We examined SIRS
scores 2 days prior through 14 days after the first positive blood culture. Vancomycin resistant (n
= 17) and susceptible infections (n = 33) were compared. Variables significant in univariate analysis
were entered into a logistic regression model to determine the affect on mortality.
Results: 60% of BSI were caused by E. faecalis and 34% by E. faecium. 34% of the isolates were
vancomycin resistant. Mean APACHE II (A2) score on the day of BSI was 16. Appropriate
antimicrobials were begun within 24 hours in 52%. Septic shock occurred in 62% and severe sepsis
in an additional 18%. Incidence of organ failure was as follows: respiratory 42%, renal 48%,
hematologic 44%, hepatic 26%. Crude mortality was 48%. Progression to septic shock was
associated with death (OR 14.9, p < .001). There was no difference in A2 scores on days -2, -1 and
0 between the VRE and VSE groups. Maximal SIR (severe sepsis, septic shock or death) was seen
on day 2 for VSE BSI vs. day 8 for VRE. No significant difference was noted in the incidence of organ
failure, 7-day or overall mortality between the two groups. Univariate analysis revealed that
AP2>18 at BSI onset, and respiratory, cardiovascular, renal, hematologic and hepatic failure were
associated with death, but time to appropriate therapy >24 hours, age, and infection due to VRE
were not. Multivariate analysis revealed that hematologic (OR 8.4, p = .025) and cardiovascular
failure (OR 7.5, p = 032) independently predicted death.
Conclusion: In patients with enterococcal BSI, (1) the incidence of septic shock and organ failure
is high, (2) patients with VRE BSI are not more acutely ill prior to infection than those with VSE BSI,
and (3) the development of hematologic or cardiovascular failure independently predicts death.
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Background
Over the past two decades, enterococcal bloodstream
infections (BSI) have become increasingly pervasive. They
account for a significant proportion of nosocomial BSI,
and are now the third most common cause of nosocomial
BSI [1]. Vancomycin resistance is common, found in
approximately 2% of E. faecalis and 60% of E. faecium
strains isolated in the United States [1]. Despite the
increasing frequency of vancomycin-resistant enterococcal (VRE) infections, questions remain about VRE's pathogenicity and its direct clinical impact.
Patients with VRE BSI are often critically ill; it is difficult
to determine whether the associated high mortality is
directly attributable to the infecting organism or a marker
of the patients' severe illness. Many studies have
attempted to address this question, with conflicting
results. Several have attributed high levels of morbidity
and mortality to VRE [2-7]. Others have been unable to
link increased mortality to vancomycin-resistance, demonstrating that vancomycin resistance is more of a marker
of severe disease than a direct cause of poor outcome [811]. Most of the studies investigating enterococcal bloodstream infections (BSI), analyze predisposing factors and
outcome measures, without closely examining the clinical
course of patients through the infection. This study was
conducted to evaluate the inflammatory response, clinical
course and outcome of nosocomial bloodstream infections due to enterococci, as well as the effects of vancomycin resistance.

Methods
Setting
The Virginia Commonwealth University Medical Center
(VCUMC) is an 820-bed, tertiary care facility in Richmond, Virginia. The hospital has nine intensive care units
(ICUs), including pediatric ICUs and a burn unit. Approximately 30,000 patients are admitted annually. The study
was approved by our Institutional Review Board.
Study design
Using the Surveillance and Control of Pathogens of Epidemiological Importance (SCOPE) database [1], we identified all patients diagnosed with enterococcal BSI at
VCUMC from November 2000 through December 2002.
Patients were considered to have had an enterococcal BSI
if they had at least one blood culture positive for this
organism. Only monomicrobial BSI were included. Clinical data were retrospectively collected, including age, gender, location of the patient, clinical service, duration of
hospitalization prior to onset of BSI, predisposing clinical
conditions, the bloodstream pathogen and its antimicrobial susceptibilities. Predisposing clinical conditions
included neutropenia (defined as an absolute neutrophil
count of less than 500/μl), peritoneal or hemodialysis,
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mechanical ventilation, total parenteral nutrition, transfusion, antibiotic use, ICU stay, and intravascular catheters
(i.e., central or peripheral intravenous catheters). Adverse
outcomes that occurred during the hospital stay were
recorded, including organ system failure and death.
Accordingly, we evaluated only in-hospital mortality.
Patients discharged from the hospital in less than seven
days from the onset of BSI were assumed to be alive at
seven days. The clinical condition of the patient was classified daily according to the systemic inflammatory
response syndrome (SIRS) criteria (SIRS, sepsis, severe
sepsis or septic shock) and APACHE II scores from two
days prior through 14 days after onset of BSI. Patients who
had nosocomial BSI due to vancomycin-resistant enterococci were compared with patients who had nosocomial
BSI due to vancomycin-susceptible enterococci.
Definitions
The date the positive blood culture was drawn was
deemed Day 0 in the tracking of BSI. The patients' physiologic condition prior to the BSI and on the day of BSI
were assessed using the APACHE II score. A cut-point of
greater than 18 was used to stratify the severity of clinical
condition. This methodology was used to be consistent
with our previous studies in this area. The clinical condition of each patient during the bloodstream infection was
classified daily as SIRS, sepsis, severe sepsis or septic shock
using criteria previously published by the American College of Chest Physicians/Society of Critical Care Medicine
(ACCP/SCCM). [12] Systemic inflammatory response
syndrome (SIRS) was defined as two or more of the following: (1) temperature >38°C or <36°C, (2)heart rate
>90 beats per minute, (3) respiratory rate >20 breaths per
minute or a PaCO2 <32 mmHg, or (4) white blood cell
count >12 × 109/L or <4 × 109/L or the presence of more
than 10% immature neutrophils. Sepsis was defined as
SIRS associated with Enterococcus isolated from at least
one blood culture. Sepsis associated with organ dysfunction, hypotension or systemic manifestations of hypoperfusion constituted severe sepsis. Septic shock was defined
as sepsis associated with hypotension unresponsive to
intravenous fluid challenge or the requirement of a vasopressor agent. SIRS 0–4, severe sepsis, septic shock and
death were used as mutually exclusive categories, with
SIRS 0, 1, 2, 3, and 4 representing the sum of the clinical
criteria used to score SIRS. The presence of organ system
failure was assessed using the criteria described by Fagon
[14]. Nosocomial infection and sources of infection were
defined according to Centers for Disease Control and Prevention (CDC) criteria [14]. Adequate empiric antimicrobial therapy was defined as treatment administered within
24 hours of the positive blood culture with an agent to
which the enterococcal isolate was susceptible. Per CDC
definitions, if the patient had a central venous catheter
present at the time of BSI and did not have an infection
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with the same organism at a different site, the infection
was determined to be central venous catheter-related.
Microbiological methods
Blood cultures were processed at the VCUMC clinical laboratory. After identifying to Enterococcus genus, a Strep API
kit was used to determine species. Minimum inhibitory
concentrations were determined using the E-test. Results
were confirmed using a microbroth dilution method
according to the Clinical and Laboratory Standards Institute. Vancomycin resistance was defined as an MIC ≥ 32
μg/mL.
Statistical analysis
Results were expressed as a mean ± SD, or as a proportion
of the total number of patients or isolates. For continuous
variables, mean values were compared using two sample
t-tests for independent samples. Differences in proportions were compared using a Chi-square test or Fisher's
Exact Test, as appropriate. Mean values are reported ± SD.
All tests of significance were two-tailed, with α set at 0.05.
Independent predictors of the outcome of BSI were identified by means of stepwise logistic regression analysis,
with a limit for entering and removing variables at 0.05.
Our dependent variable was mortality, either 7-day or
total in-hospital. All statistical analyses were done using
SPSS software (SPSS Inc., Chicago, IL, USA).

crobial BSIs caused by Enterococcus spp were analyzed
(Table 1). Patients included in the study had a mean age
of 52 years, and 50% of patients were female.
Forty-three (86%) patients had primary, catheter-related
infections. Seven patients had secondary BSI, with four
stemming from urinary tract infections and one each from
an infected wound, an infected peritoneal fluid and an
abscess. Thirty-seven (74%) of the nosocomial BSIs
occurred in the ICU setting. The patients were nearly
evenly divided among internal medicine and surgery services (48% were on the internal medicine service, 44%
were on the surgery service, and 8% were on the hematology-oncology service). The admitting diagnoses were classified as hepatic (22%), cardiac (18%), cancer (12%),
pulmonary (12%), GI (10%), trauma (10%), neurologic
(8%) and transplantation (6%).

Results

Among potential factors predisposing to BSI, intravascular
devices were the most common, with 44 patients (88%)
having central venous catheters. Prior to BSI, thirty
patients (60%) required mechanical ventilation, while 26
patients (52%) received blood products, 9 patients (18%)
underwent hemodialysis, 6 patients (12%) received total
parenteral nutrition and 3 patients (6%) were neutropenic. The mean length of hospital stay prior to BSI was
21 days. Five patients (10%) were discharged within seven
days of onset of BSI. Mean APACHE II score on day of BSI
was 16.

Study populations and patient characteristics
During the study period, a total of 330 nosocomial enterococcal BSIs were identified. Twenty-two were in pediatric patients (age <18 years), 245 were polymicrobial, and
13 had incomplete records. The remaining 50 monomi-

Microbiological features
Of the 50 enterococcal isolates, thirty (60%) were E. faecalis and seventeen (34%) were E. faecium. The remaining
three isolates were E. durans, E. gallinarum and E. casseli-

Table 1: Patient characteristics stratified by resistance pattern of infecting organism (VRE vs. VSE) and underlying severity of illness
before infection.

Mean age (years)
Women
Mean LOS prior to BSI (days)
Mechanical ventilation
Hemodialysis
TPN
Transfusion
Prior antibiotics
ICU care
Central venous catheter
Neutropenia
Vancomycin resistance
AP2>18 at day 0
Mean time to appropriate antimicrobial therapy (days)

Total (n = 50)

VSE (n = 33)

VSE (n = 17)

AP≤18 (n = 38)

AP2>18 (n = 12)

52
50%
21
60%
18%
12%
52%
84%
74%
88%
6%
34%
24%
1.4

53
48%
16*
54%
12%
6%
48%
78%
73%
88%
3%

49
53%
30*
71%
29%
23%
59%
94%
76%
88%
12%

48*
55%
22
55%
13%
16%
50%
86%
76%
87%
8%
34%

63*
33%
18
75%
33%
0%
58%
75%
67%
92%
0%
23%

24%
1.3

23%
1.7

1.6*

0.8*

(APACHE II scores on day of onset of illness >18 or ≤ 18)
*P < 0.05
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flavus. Seventeen (34%) (all E. faecium) isolates were vancomycin resistant. Three of the vancomycin-susceptible
isolates and all of the vancomycin resistant isolates were
resistant to ampicillin. Length of hospitalization (mean)
prior to BSI was longer for those patients with vancomycin-resistant than those with vancomycin-susceptible
enterococcal BSIs (30 vs. 16 days, p < 0.05). The mean
time to appropriate therapy was 1.4 days, without a statistically significant difference between the VRE and VSE
groups.
Clinical course
Septic shock occurred in 62% of patients, and severe sepsis in an additional 18%, (figure 1). The incidence of
organ failure was as follows: respiratory 42%, renal 48%,
hematologic 44%, and hepatic 26%. Seven-day mortality
was 18% and overall crude mortality was 48%, (table 2).
Progression to septic shock was significantly associated
with 7-day mortality (OR 8.5, p = 0.004) and overall mortality (OR 14.9, p < 0.001). The mean APACHE II score on
the day of BSI was 16. The APACHE II score on the day 0
of the BSI was significantly associated with mortality (OR
8.0 for those with APACHE II>18, p = 0.005) (Table 2).

There was no difference in APACHE II scores on days -2, 1, and 0 between the VRE and VSE groups. Maximal
inflammatory response (MIR; proportion of patients with
severe sepsis, septic shock or death) was seen on day 2 for
VSE BSI vs. day 8 for VRE BSI and was significantly greater
in those with VRE (Figure 3). No significant difference was
noted in the incidence of organ failure, 7-day mortality or
overall mortality between the two groups. Univariate
analysis revealed that respiratory, cardiovascular, renal,
hematologic and hepatic failure, as well as APACHE II
score>18 two days prior to BSI were associated with death,
but time to appropriate therapy >24 hours, age and infection due to VRE were not.
Variables that were statistically significant in univariate
analyses were selected for multiple logistic regression.
Multivariate analysis revealed that hematologic failure
(OR 8.6, p = 0.04) and cardiovascular failure (OR 7.6, p =
0.06) independently predicted death.

Discussion
Our study investigated monomicrobial enterococcal BSI.
Of the 308 infections in adult patients analyzed, only

100%
90%
80%

Patients (%)

70%
60%
50%
40%
30%
20%
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-2
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-1
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5
6
7
Time (days)
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Figure 1Inflammatory response (SIRS) over time in patients with enterococcal BSI
Systemic
Systemic Inflammatory response (SIRS) over time in patients with enterococcal BSI.
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Table 2: Patient outcomes stratified by resistance pattern of infecting organism (VRE vs. VSE) and underlying severity of illness before
infection.

Respiratory failure
Cardiovascular failure
Renal failure
Hematologic failure
Liver failure
7-day mortality
Overall mortality

Total (n = 50)

VSE (n = 33)

VRE (n = 17)

AP2≤18

AP>18

42%
40%
48%
44%
26%
18%
48%

42%
42%
42%
33%*
24%
15%
42%

41%
35%
59%
65%*
29%
23%
59%

32%*
34%
39%*
42%
24%
13%
39%*

75%*
58%
75%*
50%
33%
33%
75%*

(APACHE II scores on day of onset of illness >18 or ≤ 18)
*P < 0.05

16% (50) of these were monomicrobial, which is lower
than in other reports [5,6]. The patients in our study were
severely ill by several markers. The mean length of hospitalization prior to BSI was long (21 days), which is consistent with nationwide trends [1]. The majority (74%)
were cared for in intensive care settings at the onset of
their BSI. They also had significant mortality, with 18% 7day mortality and 48% overall mortality. Our patients
also had a high level of resistant infecting organisms; 34%
of the enterococcal isolates were resistant to vancomycin.
Many studies in the past 15 years have examined the role
of vancomycin resistance on the outcome of enterococcal
infections. Results have varied, with several demonstrating an association between vancomycin resistance and
higher mortality. A 2003 meta-analysis of studies comparing outcomes in VRE and VSE bacteremia reported that,
though most individual studies were insufficiently powered or adjusted to make this judgment, the available data
suggested the VRE infections conferred higher mortality
[7]. Few studies, however, have closely monitored
patients' clinical courses throughout the hospital stay. We
therefore investigated the systemic inflammatory
response, clinical course and outcome of enterococcal BSI,
stratifying by vancomycin susceptibility.
To characterize the severity of the patients' clinical condition and inflammatory response throughout the course of
infection, we measured APACHE II scores and SIRS criteria from two days prior through 14 days after the onset of
enterococcal BSI. Through univariate analysis, we found
that patients' clinical state at onset of BSI influenced their
mortality; patients with APACHE II>18 did significantly
worse than those with APACHE II<18, (figure 2). When
stratifying for vancomycin-susceptibility, there was no difference in APACHE II scores on the day of infection or the
two days preceding infection between the VRE and VSE
groups. Despite the similar clinical state at onset of infection, the VRE group had a greater inflammatory response
that peaked later in hospitalization than the VSE group.
Maximal inflammatory response was seen on day 2 for the

VSE group and day 8 for the VRE group, (figure 3). Progression to septic shock was significantly associated with
7-day and overall mortality. The greater inflammatory
response of VRE species, however, did not translate into
different outcomes as there was no statistical difference in
incidence of organ failure, 7-day mortality or overall mortality. Our study showed non-significant trends toward
increased mortality in the VRE group, and it is possible
that with the increased power of a larger sample size, the
greater inflammatory response would have correlated
with increased mortality.
The enterococcal isolates in our study were predominantly E. faecalis and E. faecuim. The vancomycin resistance pattern followed speciation, with all of the E. faecalis
isolates being vancomycin susceptible and all of the E.
feacium isolates being vancomycin resistant. This is somewhat divergent from national surveys which report 60%
vancomycin-resistance in E. faecium isolates. [1] Additionally, this raises the possibility that other factors innate to
the particular species, besides antimicrobial resistance
pattern, could influence the clinical course in our analysis.
Earlier investigations have associated E. faecium with
higher mortality than E. faecalis; either because it tends to
colonize and infect sicker patients or because it is inherently more virulent. [15] In a study controlling for species
by comparing VRE vs. VSE in E. faecium species alone, no
increase in mortality was associated with vancomycin
resistance [9].
Similar to other studies, our analysis demonstrated longer
hospitalization was a risk factor for VRE infection, with
mean length of stay of 30 days in the VRE group and 16
days in the VSE group. Age, sex, prior antibiotic use,
mechanical ventilation, hemodialysis, stay in intensive
care setting, central venous catheter use and neutropenia
were not significant risk factors for vancomycin resistance
in this study.
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Appropriate antimicrobial therapy within 24 hours of
infection was not a significant determinant of mortality.
This differs from past studies, where appropriate antimicrobials were more rapidly used in VSE infections. This
likely reflects the evolution of available antimicrobials –
with linezolid and quinupristin/dalfopristin being available during this study period, but not, or only on an investigational or compassionate-use-basis, in most earlier
studies. These newer treatment options may change the
mortality associated with VRE bacteremia. The more
severely ill patients (those with APACHE II>18), did
receive appropriate antimicrobial therapy significantly
sooner (0.8 days versus 1.6 days), perhaps reflecting more
aggressive clinical care or broader antibiotic coverage.
The presence of organ system failure was measured to further evaluate clinical course. Univariate analysis revealed
that all measured forms of organ failure (respiratory, cardiovascular, renal, hematologic and liver) were associated
with death. Multivariate analysis revealed that hematologic and cardiovascular failure independently predicted

death. It is notable that hematologic failure, as defined by
Fagon [13], includes the criterion of platelets <100,000/
μL. This may have been affected by use of linezolid, which
is associated with thrombocytopenia and may confound
this result [16].
This study failed to associate an increased inflammatory
response in VRE BSI to significantly increased mortality.
The underlying clinical state was significant in determining outcome, whereas the resistance pattern of the infecting organism and appropriate antimicrobial therapy were
not. This supports other studies in which the enterococcal
BSI were found to have insignificant impact on clinical
outcome. These results have been attributed to the low virulence of enterococcal species. However, similar results
were found in several recent studies with common methodology analyzing more virulent pathogens (Staphylococcus aureus, Candida spp and Pseudomonas aeruginosa). In
these analyses, the underlying clinical condition (as measured by APACHE II score) was also significant, while the
resistance pattern or appropriate antimicrobial therapy
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were not. [17-19]. This furthers the concept that the host,
rather than the pathogen, more greatly affects clinical outcome.

Conclusion
The overall morbidity and mortality of patients with enterococcal BSI is high. Morbidity correlates closely with the
clinical condition of patient at the time of infection as
measured by APACHE II score, regardless of vancomycin
susceptibility pattern. Though showing a trend toward

greater and later peaking inflammatory state, vancomycin
resistance did not predict outcome. Timely treatment with
appropriate antimicrobials also did not predict outcome.
However, hematologic and cardiovascular failure predicted death.
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